{"id":468780,"date":"2025-12-23T00:00:00","date_gmt":"2025-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0001-2025-biopharma-hospital-treated-gram-negative-infections-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:42","modified_gmt":"2026-03-31T10:23:42","slug":"dlsfid0001-2026-biopharma-hospital-treated-gram-negative-infections-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0001-2026-biopharma-hospital-treated-gram-negative-infections-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Hospital-Treated Gram-Negative Infections &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Due to the rising rates of antimicrobial resistance, antibiotics with activity against drug-resistant gram-negative pathogens are essential. Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (<abbr title=\"gram-negative infection\">GNI<\/abbr>) armamentarium. Despite the approval of novel antibiotics such as Shionogi\u2019s Fetroja \/ Fetcroja, Innoviva\u2019s Xacduro, and AbbVie \/ Pfizer\u2019s Emblaveo, additional treatments with novel mechanisms of action that are effective in patients with drug-resistant infections are needed. Although the market is heavily genericized and cost-containment measures limit the commercial success of new therapies, innovative push-and-pull market approaches such as value-based pricing and de-linked drug reimbursement models continue to encourage and support antibiotics development.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large are the treatable <abbr title=\"hospital-acquired bacterial pneumonia\">HABP<\/abbr> \/ <abbr title=\"ventilator-associated bacterial pneumonia\">VABP<\/abbr> \/ <abbr title=\"healthcare-acquired pneumonia\">HCAP<\/abbr>, <abbr title=\"complicated skin and skin structure infection\">cSSSI<\/abbr> \/ <abbr title=\"surgical-site infection\">SSI<\/abbr>, <abbr title=\"complicated intra-abdominal infection\">cIAI<\/abbr>, <abbr title=\"bloodstream infection\">BSI<\/abbr>, and <abbr title=\"urinary tract infection\">UTI<\/abbr> populations, and what are the resistance rates to different classes of antibiotics across several pathogen species?<\/li>\n<li>What is the state of treatment for hospital-treated <abbr title=\"gram-negative infection\">GNI<\/abbr>s, and which clinical needs remain unfulfilled?<\/li>\n<li>How will increasing genericization during the forecast period impact the use of branded antibiotics?<\/li>\n<li>What impact will newer-to-market and emerging antibiotic therapies have on the hospital-treated <abbr title=\"gram-negative infection\">GNI<\/abbr> therapy market?<\/li>\n<\/ul>\n<p><strong>Geographies<\/strong>: United States, France, Germany, Italy, Spain, United Kingdom, Japan<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading infectious disease specialists. Survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed events of <abbr title=\"gram-negative infection\">GNI<\/abbr>s by country, segmented by key infections; pathogens (<i>E. coli, Pseudomonas, Acinetobacter, Klebsiella<\/i>); and resistance types.<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key antibiotics through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies.<\/p>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-468780","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/468780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/468780\/revisions"}],"predecessor-version":[{"id":575231,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/468780\/revisions\/575231"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=468780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}